placeholder
Importance
60
Trust
71
Urgency
30
CLINICAL TRIAL
Partner advances Gubra originated obesity triple agonist peptide into phase 2 - marketscreener.com
A partner of Gubra is moving a triple-action weight-loss peptide (a drug that works three different ways) into Phase 2 testing (a mid-stage trial to check if it works and is safe). The peptide was originally created by Gubra, a Danish research company.
Analysis
A new triple-action weight-loss peptide is moving into mid-stage human testing. It could one day compete with Lilly's retatrutide in the obesity drug race.
- Gubra-originated triple agonist peptide advancing to Phase 2
- Drug is being developed by an unnamed Gubra partner
- Targets obesity via three-receptor mechanism
Retatrutide News1mo
Read